Brief: Mezzion Reports Pre-Ind FDA Feedback On The Development Of Udenafil In Adpkd
07/05/2026 14:28
May 7 (Reuters) - Mezzion Pharma Co Ltd 140410.KQ: MEZZION REPORTS PRE-IND FDA FEEDBACK ON THE DEVELOPMENT OF UDENAFIL IN ADPKD MEZZION PHARMA CO LTD - FDA SAYS MEZZION DATA MAY SUPPORT CLINICAL DEVELOPMENT OF UDENAFIL MEZZION PHARMA CO LTD - PLANS TO ADVANCE UDENAFIL TO PHASE 2 AND PHASE 3 IN ADPKD Source text: ID:nPn6yhFRha Further company coverage: 140410.KQ ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mezzion Pharma
See all newsBrief: Mezzion Secures Strategic Financing To Support Advancement Of Global Phase 3 Fuel-2 Trial In Fontan Patients
Brief: Mezzion Reports Pre-Ind FDA Feedback On The Development Of Udenafil In Adpkd
Brief: Mezzion Pharmaceuticals Appoints Ridwan Shabsigh As President & Chief Operating Officer
Brief: Mezzion Pharmaceuticals Reaches Key Enrollment Milestone In World's Largest Fontan Clinical Trial
Brief: Mezzion Pharmaceuticals Announces Dr Rahul Rathod As Global Principal Investigator For The Confirmatory Pivotal Phase 3 Trial FUEL-2